EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open‐Label Randomized Clinical Trial

Chengmei He iD, Yi Wei iD, Kunyu Zheng, Xu Wang, Jia Liu, Mengtao Li, Li Wang iD, Fengchun Zhang

Journal of Gastroenterology and Hepatology · 2026-08 · 41 (8) · 2458-2466

DOI: 10.1111/jgh.70554 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 07.07.2026. Verfasst von Chengmei He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical…. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, Liver Cirrhosis, Biliary, Cholagogues and Choleretics, Drug Tapering. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CAMS Innovation Fund for Medical Sciences, Non-profit Central Research Institute Fund of Chinese Academy of Medical Science, Capital Health development Research Special Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Ursodeoxycholic acid (UDCA) is first‐line therapy for primary biliary cholangitis (PBC), evidence for dose reduction after biochemical remission remains limited. This study aimed to evaluate the feasibility and safety of UDCA reduction in PBC.

Methods

In this open‐label randomized controlled clinical trial, PBC patients who reached complete biochemical response (Paris‐II criteria) after ≥ 6 months of standard 13–15 mg/kg/day UDCA therapy were prospectively enrolled. Eligible patients were assigned in a 1:1:1 ratio to receive either (1) continued 13–15 mg/kg/day, (2) 10 mg/kg/day, or (3) 5‐mg/kg/day UDCA. The primary endpoint was biochemical relapse rate within 12 months. Secondary endpoints included changes in liver biochemistry, changes in patient‐reported symptoms, and changes in GLOBE and UK‐PBC scores, as well as adverse events.

Results

From January 2020 to March 2024, 96 patients who complied with the protocol after randomization were analyzed. Within the 12‐month follow‐up period, the relapse rates in the three groups were 0%, 2.9%, and 19.4%, respectively (overall p = 0.008). Secondary outcomes showed no significant intergroup differences. In patients with a disease relapse, prompt retreatment with a standard dose of UDCA could help liver function recover. No severe adverse events were observed.

Conclusions

The relapse rate in the 5‐mg/kg/day group was significantly higher than that in the standard‐dose group, necessitating close clinical monitoring, and no significant difference in relapse was observed between the 10 mg/kg/day and standard‐dose group, suggesting it may be a potential dose‐reduction strategy, though further studies are needed for confirmation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ursodeoxycholic AcidLiver Cirrhosis, BiliaryCholagogues and CholereticsDrug TaperingHumansFemaleMiddle AgedMaleTreatment OutcomeAgedRecurrenceProspective StudiesBiomarkersFeasibility StudiesFollow-Up StudiesDose-Response Relationship, DrugTime FactorsAdult

Stichwörter der Autor:innen

cost of illnessdrug taperingprimary biliary cholangitisursodeoxycholic acid

Substanzen

Ursodeoxycholic AcidCholagogues and CholereticsBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Mini…
  • Department of Ultrasound, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Medical Science and Technology Evaluation, Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Chengmei He, Yi Wei, Li Wang

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Science
  • Capital Health development Research Special Fund
  • Postdoctoral Fellowship Program of CPSF

Zitieren

APA

He, C., Wei, Y., Zheng, K., Wang, X., Liu, J., Li, M., Wang, L., & Zhang, F. (2026). Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open‐Label Randomized Clinical Trial. Journal of Gastroenterology and Hepatology, 41(8), 2458-2466. https://doi.org/10.1111/jgh.70554

Vancouver

He C, Wei Y, Zheng K, Wang X, Liu J, Li M, et al. Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open‐Label Randomized Clinical Trial. Journal of Gastroenterology and Hepatology. 2026;41(8):2458-2466. doi:10.1111/jgh.70554

BibTeX
@article{He2026,
  author = {He, Chengmei and Wei, Yi and Zheng, Kunyu and Wang, Xu and Liu, Jia and Li, Mengtao and Wang, Li and Zhang, Fengchun},
  title = {Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open‐Label Randomized Clinical Trial},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {8},
  pages = {2458--2466},
  doi = {10.1111/jgh.70554}
}
Kostenlos starten →